|
市場調查報告書
睡眠障礙：宣傳和察覺有利於擴大市場嗎？
Sleep Disorders: Promotion and Awareness Will Drive Market Growth
|
本報告已在2011年12月21日停止出版。
全球主要國家中有2000萬以上的人患有睡眠障礙。2005年主要4種睡眠障礙治療藥的銷售總額超過30億美元，其中失眠症的比例為82%。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對睡眠障礙治療藥的趨勢進行調查分析，經系統整理調查結果後出版報告書 "Sleep Disorders: Promotion and Awareness Will Drive Market Growth" 。
本報告書以失眠症、嗜睡病（瞌睡病）、肢體不安症候群（腿抽動及刺癢症候群）、睡眠呼吸中止症候群4種睡眠障礙為調查重點，內容包括：個別病因及患者趨勢、目前及新興的治療方法之檢驗，以及美國、歐洲及日本2005年至2015年的市場預測等。內容綱要摘記如下：
序章
失眠症簡介
- 病因與患者人數
- 目前的治療方法
- 苯二氮平類藥（Benzodiazepines）
- 非苯二氮平類藥
- 褪黑激素對抗藥
嗜睡病
肢體不安症候群
睡眠呼吸中止症候群
睡眠障礙市場
新興治療方法
- 失眠症
- 5-HT2a對抗藥
- GABA促效藥
- H1對抗藥
- 褪黑激素促效藥
- 嗜睡症
- 肢體不安症候群
- 睡眠呼吸中止症候群
市場展望
Abstract
Sleep disorders affect more than 200 million people worldwide. It is generally
accepted that insufficient sleep contributes significantly to automobile
accidents and fatalities, work-related injuries, mood depression, and, in
general, impaired health. Nevertheless, all sleep disorders are significantly
undertreated. This level of unmet need presents a significant market
opportunity, and sleep disorders increasingly attract the attention of
pharmaceutical companies. Additionally, the imminent patent expiration of the
blockbuster agent zolpidem (Sanofi-Aventis's Ambien) has attracted the
attention of generics manufacturers. Consequently, the sleep disorders market
is likely to experience great change over the next ten years. In this report,
we focus on the four sleep disorders thought to have major significance for
physical and mental health: insomnia, narcolepsy, restless legs syndrome
(RLS), and sleep apnea. We examine their etiology and prevalence, current and
emerging therapies, the state of the current market, and the outlook for the
sleep disorders market in the United States, Europe, and Japan during the
period 2005-2015.
Table of Contents
- Introduction
- Overview of Insomnia
- Etiology and Prevalence
- Current Therapies
- Benzodiazepines
- Non-Benzodiazepines
- Melatonin Antagonists
- Narcolepsy
- Etiology and Prevalence
- Current Treatments
- Restless Legs Syndrome
- Etiology and Prevalence
- Current Treatments
- Sleep Apnea
- Etiology and Prevalence
- Current Treatments
- The Sleep Disorders Market
- Emerging Therapies
- Insomnia
- 5-HT2a Antagonists
- GABA Agonists
- H1 Antagonists
- Melatonin Agonists
- Narcolepsy
- Restless Legs Syndrome
- Sleep Apnea
- Market Outlook
- United States
- Europe
- Japan
- Table 1 Prevalence of Sleep Disorders, 2005
- Table 2 Sales of Leading Agents for the Treatment of Sleep Disorders, 2005
- Table 3 Agents in Development for Treatment of Insomnia, 2006
- Table 4 Agents in Development for the Treatment of Narcolepsy, Restless
Legs Syndrome, and Sleep Apnea
- Table 5 Forecasted Sales of Drugs for the Treatment of Sleep Disorders in
the Three Major-Market Regions, 2010 and 2015
|
